TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00971542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study: NCT01954810

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Japanese encephalitis chimeric vaccine (JECV)
Description: Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
Study: NCT03233711

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy
Description: Undergo proctoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proctoscopy
Description: Undergo proctoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-ray

Intervention type: PROCEDURE
Group type: OTHER
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study: NCT03046251

Intervention type: DRUG
Group type: OTHER
Intervention: Natalizumab
Study: NCT03374436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Sedentary
Description: Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
Study: NCT03184233

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rapid ventricular pacing
Description: Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No rapid ventricular pacing
Description: No rapid ventricular pacing is applied perioperatively.
Study: NCT03374436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Active
Description: Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks.
Study: NCT01038440

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA
Description: Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA
Description: Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SDA
Description: Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SDA
Description: Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SDA
Description: Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SDA
Description: Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
Study: NCT01367665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: 150 mg once daily until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: 150 mg once daily until disease progression or unacceptable toxicity
Study: NCT02497651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid mixed meal
Description: The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid mixed meal
Description: The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
Study: NCT03374436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-carbohydrate Sedentary
Description: Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
Study: NCT01503619

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00675662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Lifestyle intervention with Trim Tots pre-school programme.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting list control
Description: waiting list control
Study: NCT02244008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: joint mobilization
Description: The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual contact
Description: The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
Study: NCT03674541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine Bromide
Description: Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose
Study: NCT02580591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For blinding purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For blinding purposes
Study: NCT03336060

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical Correlates of Jump Landing Task
Description: The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cortical Correlates of Jump Landing Task
Description: The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
Study: NCT02283541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automatic self-transcending meditation
Description: ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
Study: NCT01785498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplementary resources
Description: Clinical and educational resources for patients, their families and the professionals who care for them.
Study: NCT03793634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical chamomile
Description: herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical chamomile
Description: herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
Study: NCT02978170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT
Study: NCT03704389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Clinical decision support nudges within the electronic health record
Study: NCT02451189

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin acetate ester
Description: Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin propionate ester
Description: Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin butyrate ester
Description: Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
Study: NCT00863941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg XL Tablet, single dose
Description: A: Experimental Subjects received Abrika formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin XL® 150 mg Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Study: NCT04090697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
Study: NCT01301755

Intervention type: PROCEDURE
Intervention: Lung aspiration
Description: direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
Study: NCT03411434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Oral Tablet
Description: cf arm group description
Study: NCT04884906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/m2, iv, d1, Q3W, a total of 6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 1.8-2.15Gy/time (radiotherapy started on the 8th day of camrelizumab treatment), a total of 28 times (5 times a week), a total of 50.4-60.2Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: 260mg/m2, iv, d1, Q3W, a total of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80-120mg/m2, iv, d1-3, Q3W, a total of 6 cycles
Study: NCT02562976

Intervention type: OTHER
Intervention: gastric atrophy and intestinal metaplasia
Description: use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia

Intervention type: OTHER
Intervention: gastric atrophy and intestinal metaplasia
Description: use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
Study: NCT01838304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Probability ramp control
Description: Decision support software that calculates propofol doses appropriate for age and weight of the patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring
Description: Manual recording of drug doses determined by CRNA
Study: NCT03225560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel Preparation
Description: Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bowel Preparation
Description: Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
Study: NCT00925067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic (TEP) inguinal hernia repair
Description: laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic (TEP) inguinal hernia repair
Description: laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic (TEP) inguinal hernia repair
Description: laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lightweight TiMesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lightweight VyproII

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heavyweight Marlex
Study: NCT01546090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: preoperative administration of an orally 0.50 mg single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules were filled with starch
Study: NCT00595868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: same as Varenicline arm
Study: NCT00331084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic/steroid combination
Description: 1 gtt, 4x/day, 15 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin / dexamethasone
Description: 1 gtt 4x/day, 15 days
Study: NCT02498327

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatine Capsule
Description: Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venavine Intensive®
Description: Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
Study: NCT04057040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02483065

Intervention type: OTHER
Intervention: mortality at discharge and 3-months after the admission in patients with and without dementia
Description: Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.

Intervention type: OTHER
Intervention: mortality at discharge and 3-months after the admission in patients with and without dementia
Description: Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
Study: NCT01996436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Description: Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine + Verapamil + Nitroglycerin
Description: Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
Study: NCT03108300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: propranolol hydrochloride is a beta-adrenergic receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
Study: NCT04072536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric wheelchair with activated assistance module
Description: This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance

Intervention type: DEVICE
Group type: OTHER
Intervention: Electric wheelchair with assistance module not activated
Description: This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
Study: NCT03868670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: responsive neurostimulation
Description: The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.